Intravenous immune globulin did not significantly augment the improvement in left ventricular fractional shortening or end diastolic dimensions compared to placebo in children with acute onset dilated cardiomyopathy.
RCT (n=86)
Placebo-controlled
Random table block (initial block of 2-treatment) stratified by clinical centre
p-value: p=>0.05
In the cardiomyopathy clinic of Cairo University Children Hospital (tertiary care centre) we are faced with a large number of cases per year (>60) presenting with recent onset dilated cardiomyopathy. The limited resources the hospital has made it difficult to provide IVIG for all such patients. This is complicated by the fact that the use of IVIG is controversial in the medical literature. Accordingly, a prospective randomized study was performed to evaluate the potential role of intravenous immune globulin therapy in childhood acute onset dilated cardiomyopathy and to determine the best timing for its usage.
Sonia A. El-Saiedi (Wed,) conducted a rct in Acute onset dilated cardiomyopathy or myocarditis (n=86). Intravenous Immune Globulin (IVIG) vs. Placebo (5% glucose IV fluids) was evaluated on Change in fractional shortening (FS) and left ventricular end diastolic dimension (LVEDD) from baseline to 6 months (p=>0.05). Intravenous immune globulin did not significantly augment the improvement in left ventricular fractional shortening or end diastolic dimensions compared to placebo in children with acute onset dilated cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: